A method of screening the antitumor lead compounds based on the dynamic bio-response profile of cells.
- Author:
Li-Na MA
;
Le-Le ZHANG
;
Yin XIONG
;
Yu-Mei HAN
;
Cong-En ZHANG
;
Dan GAO
;
Li MA
;
Dan YAN
;
Xiao-He XIAO
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Biosensing Techniques;
methods;
Cell Count;
Cell Line, Tumor;
Cisplatin;
pharmacology;
Drug Screening Assays, Antitumor;
Electric Impedance;
Humans
- From:
Acta Pharmaceutica Sinica
2014;49(5):695-700
- CountryChina
- Language:Chinese
-
Abstract:
The study is to report the establishment of a method of screening the antitumor compounds based on the dynamic bio-response profile of cells to make up for the shortages of conventional end-point tests such as tedious operation and low sensitivity. Based on the principle of electric impedance of cells, the real-time cell electronic sensing (RT-CES) system was used to monitor the effect of epirubicin (EPI), cisplatinum (DDP) and carboplatin (CBP) on the growth of HepG2 cells, with the cell index (CI), half maximal inhibitory concentration (IC50) and detachment curve as evaluation indexes. Meanwhile, cell counting kit-8 (CCK-8) and microscopy were applied for verification. The results showed that CI curve could sensitively real-time profile the inhibitory effect of model drugs on HepG2 cells. The IC50 of EPI, DDP and CBP were 0.53 +/- 0.04, 9.79 +/- 0.26 and 597.00 +/- 3.79 microg x mL(-1), respectively. What's more, the significant differences of detachment curves of the three drugs indicated that their functional mechanisms might be different, this is consistent with the literature. The RT-CES system with non-invasive, label-free and real-time characteristics could be used to monitor the bio-response profile of the three drugs to HepG2 cells, allowing to qualitatively and quantitatively distinguish the antitumor activities of the three drugs, and could be a complementary method for the present screening of antitumor compounds.
